The financials
Elanco Animal Health Incorporated by the numbers
Elanco Animal Health Incorporated (ELAN) reported revenue of $1.37B in Q2 2026 (quarter ended Jun 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $54M (3.9% of revenue). For the full year FY2025, revenue was $4.71B (+6.2% year on year) and net income −$232M. Its largest product in Q2 2026 was Farm Animal at $633M, 49% of the disclosed total, well ahead of Cattle at 24%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.37B | $1.24B | +10% |
| Gross profit | $798M | $713M | +12% |
| Net income | $54M | $11M | +391% |
| Diluted EPS | $0.11 | $0.02 | +450% |
| Product | Revenue | Share |
|---|---|---|
| Farm Animal | $633M | 49% |
| Cattle | $313M | 24% |
| Poultry | $223M | 17% |
| Swine | $97M | 7.6% |
| Contract Manufacturing | $17M | 1.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.28B (-1.5%)
Cattle grew +17% year on yearSwine -3.0% year on year
Segment Latestquarter on quarteryear on year
- Farm Animal$633.0M$633.0MQoQ -1.4%year on year +8.6%-1.4%+8.6%
- Cattle$313.0M$313.0MQoQ -0.95%year on year +17%-0.95%+17%
- Poultry$223.0M$223.0MQoQ -3.0%year on year +3.7%-3.0%+3.7%
- Swine$97.0M$97.0MQoQ +1.0%year on year -3.0%+1.0%-3.0%
- Contract Manufacturing$17.0M$17.0MQoQ -11%year on year +13%-11%+13%
Drug Manufacturers - Specialty & Generic
Ranks #17 of 29 by Smart Score